|
DBR1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.32827124036339E-15 |
| Normal-vs-Stage2 |
1.50475999999289E-05 |
| Normal-vs-Stage3 |
1.19793064357054E-13 |
| Normal-vs-Stage4 |
1.63169477929159E-12 |
| Stage1-vs-Stage2 |
1.478390E-01 |
| Stage1-vs-Stage3 |
1.867230E-01 |
| Stage1-vs-Stage4 |
2.260800E-03 |
| Stage2-vs-Stage3 |
3.559700E-02 |
| Stage2-vs-Stage4 |
1.575510E-03 |
| Stage3-vs-Stage4 |
1.280400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.73359999999789E-06 |
| Normal-vs-Asian |
1.62506999999978E-05 |
| Caucasian-vs-AfricanAmerican |
7.135200E-01 |
| Caucasian-vs-Asian |
2.228400E-02 |
| AfricanAmerican-vs-Asian |
2.825400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
9.07052211118753E-14 |
| Normal-vs-Female |
1.62503344114384E-12 |
| Male-vs-Female |
7.522200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.67765801251107E-12 |
| Normal-vs-Age(41-60Yrs) |
1.50202073001537E-12 |
| Normal-vs-Age(61-80Yrs) |
1.70508052121932E-12 |
| Normal-vs-Age(81-100Yrs) |
2.377300E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.004400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.985600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.682800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.865200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.371200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.552600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.968400E-02 |
| Classical-VS-Follicular |
4.142400E-01 |
| Classical-VS-Other |
5.491200E-01 |
| Classical-VS-Normal |
1.63680180520487E-12 |
| Tall-VS-Follicular |
2.052200E-01 |
| Tall-VS-Other |
6.857800E-01 |
| Tall-VS-Normal |
8.3157003505363E-10 |
| Follicular-VS-Other |
7.823000E-01 |
| Follicular-VS-Normal |
2.22869944721538E-10 |
| Other-VS-Normal |
2.259700E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.55686574743186E-12 |
| Normal-vs-N1 |
2.38253861084559E-13 |
| N0-vs-N1 |
9.762400E-03 |
|
|
